Highlights Cidara Therapeutics, Inc.

Equities

CDTX

US1717572069

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
11.26 ^USD	-0.53%		-7.40%	-29.09%

Jul. 01	Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell Microcap Value Index	CI
Jul. 01	Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 3000E Value Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $8.5M	May. 15	MT
Cidara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
North American Morning Briefing : More Tech Earnings in Focus With GDP Data Adding to the Uncertainty	Apr. 25	DJ
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset	Apr. 24	DJ
Mundipharma International Limited acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc..	Apr. 23	CI
Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket	Apr. 23	MT
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q4 Revenue $17.6M	Apr. 22	MT
Cidara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 22	CI
Cidara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 22	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
North American Morning Briefing : Microsoft Kicks Off Big Tech Bonanza	Jan. 30	DJ
Cidara Therapeutics Says UK Regulator Approved Invasive Candidiasis Treatment	Jan. 30	MT
Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults	Jan. 29	CI
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China	Dec. 06	CI
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id	Dec. 05	CI
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q3 Revenue $12.7M	Nov. 02	MT
Cidara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Cidara Therapeutics and Mundipharma Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults	23-10-13	CI
Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023	23-10-11	CI
Cidara Therapeutics, Inc. Announces Janssen?S Election to Proceed Under Its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza	23-09-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cidara Therapeutics, Inc.

Equities

CDTX

US1717572069

Highlights

Filters